Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

4.38
-0.2000-4.37%
Post-market: 4.36-0.0200-0.46%19:37 EDT
Volume:1.25M
Turnover:5.50M
Market Cap:608.45M
PE:-1.09
High:4.62
Open:4.58
Low:4.35
Close:4.58
52wk High:14.45
52wk Low:4.16
Shares:138.92M
Float Shares:94.55M
Volume Ratio:1.25
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0061
EPS(LYR):-3.8310
ROE:-46.22%
ROA:-24.73%
PB:0.64
PE(LYR):-1.14

Loading ...

Vir Biotechnology Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
May 06

Vir Biotechnology (VIR) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 01

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Business Wire
·
May 01

Vir Biotechnology Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Apr 18

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

Insider Monkey
·
Apr 09

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
Apr 09

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
Apr 03

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Simply Wall St.
·
Mar 31

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
Mar 31

BRIEF-Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection

Reuters
·
Mar 13

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial

MT Newswires Live
·
Mar 13

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Business Wire
·
Mar 13

CrowdStrike Fuels Partner Growth and Profitability with Expanded Accelerate Partner Program

Business Wire
·
Mar 11

Vir Biotechnology Is Maintained at Overweight by Barclays

Dow Jones
·
Mar 01

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 28

Barclays Remains a Buy on Vir Biotechnology (VIR)

TIPRANKS
·
Feb 28

Stock Track | Vir Biotechnology Plummets 9.46% as Key Pipeline Programs Remain Early-Stage

Stock Track
·
Feb 28

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents
·
Feb 28

Stock Track | Vir Biotechnology Soars 5.98% on Strong Q4 Results and Promising Outlook

Stock Track
·
Feb 27

Vir Biotechnology Price Target Maintained With a $19.00/Share by Needham

Dow Jones
·
Feb 27